The article discusses issues on the patenting of antibodies with respect to written description jurisprudence. Also cited are the promise of therapeutic antibody treatments in the biomedical sector, the complicated issues in the patenting of antibodies, the tests used by the U.S. Federal Circuit in determining the patentability of antibodies, and the case Amgen v. Sanofi.